Tirzepatide, a dual receptor agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, also reported an improvement in fibrosis biomarkers in NAFLD patients with type 2 diabetes (NCT03131687) (43). The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.